Latest Research in Ocular Pharmacological Intervention
40 research papers · 2026 median publication year
Top Research Topics in Ocular Pharmacological Intervention
- Retinal Diseases and Treatments — 34 papers
- Analysis of PDEs — 2 papers
- Biosimilars and Bioanalytical Methods — 1 papers
- Ocular Diseases and Behçet’s Syndrome — 1 papers
- Navier-Stokes equation solutions — 1 papers
- Retinal and Macular Surgery — 1 papers
Highest-Cited Papers
- Choroidal Vascular Remodeling After Loading Injections of Faricimab in Diabetic Macular Edema
- Intravitreal tissue plasminogen activator plus ranibizumab with temporal decubitus positioning versus ranibizumab monotherapy for MNV-associated submacular hemorrhage: a retrospective comparative study
- Macular neovascularisation subtype determines visual consequences of early fibro-atrophic remodelling in neovascular AMD: PRECISE study report 11
- Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy
- Early Macular Leakage Resolution Is Associated with Extended Faricimab Dosing in Retinal Vein Occlusion: A BALATON/COMINO Post Hoc Analysis
- Regularity for axisymmetric Navier-Stokes with an Euler length
- Safety of intravitreally applied epidermal growth factor receptor antibody panitumumab
- Short-Term Outcomes of Switching from the Aflibercept Biosimilar SB15 to Ranibizumab Biosimilars
- Intravitreal Anti-vascular Endothelial Growth Factor Injection Practices Among Indonesian Vitreoretinal Specialists: Findings From a 2021 National Survey
- Two-dose aflibercept 8 mg versus three-dose aflibercept 2 mg loading for treatment-naïve neovascular age-related macular degeneration
- Cost-effectiveness of biosimilar ranibizumab versus originator ranibizumab for neovascular age-related macular degeneration in the Republic of Korea
- Real-World Dosing Intervals for Long-Acting Anti-VEGF Intravitreal Injection Therapies in nAMD and DME: Academy IRIS ® Registry Analysis
- OUTCOMES OF INTRAVITREAL BEVACIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: EXPERIENCE FROM A JORDANIAN MILITARY HOSPITAL
- OUTCOMES OF INTRAVITREAL BEVACIZUMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: EXPERIENCE FROM A JORDANIAN MILITARY HOSPITAL
- One-year real-world data of intravitreal faricimab in patients with pre-treated neovascular age-related macular degeneration
- Changes in demographics and treatment trends in neovascular age-related macular degeneration during the COVID-19 pandemic in Japan
- Impact of faricimab and high‐dose aflibercept on treatment demand in a tertiary ophthalmic centre in Norway
- From Trials to Treatment: Current Evidence Supporting Faricimab Use in nAMD and DME
- Comparative effectiveness of three treatment strategies for submacular hemorrhage secondary to age-related macular degeneration
- ANATOMICAL AND FUNCTIONAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB IN MACULAR EDEMA ASSOCIATED RETINAL VEIN OCCLUSION: A SINGLE-CENTER EXPERIENCE AT PRINCE RASHID BIN AL-HASSAN MILITARY HOSPITAL
Sub-Regions
- Retinal Diseases and Treatments — 37 papers
- Analysis of PDEs — 3 papers